BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)

BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $61.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).

The analyst commented: "In an effort to track Bristol's ongoing launch of Cobenfy in schizophrenia, we are tracking weekly TRx for the drug through IQVIA. This week, Cobenfy TRx growth accelerated, rising 9% WoW reaching 1,573, another new high. Going forward, we expect Cobenfy to reach ~$29M in revenue for 1Q25 (+43% vs. current consensus). While TRx growth has been robust and consensus remains beatable, we will continue to monitor adjustments to consensus following the end of quarter ahead of earnings as sell-side reviews quarterly script data when updating estimates."

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $55.30 yesterday.

You May Also Be Interested In

• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Innovaro (INV) Misses Q2 EPS by 9c